IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. 
VERtebral Fracture Treatment Comparisons in Osteoporotic Women (VERO)
This study has been completed.
Sponsor:
Eli Lilly and Company
Information provided by (Responsible Party):
Eli Lilly and Company
ClinicalTrials.gov Identifier:
NCT01709110
First received: October 16, 2012
Last updated: July 14, 2016
Last verified: July 2016
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
The primary purpose of participation in this study is to answer whether teriparatide is superior to risedronate in reducing the occurrence of new vertebral fractures during 24 months of therapy.
| Condition | Intervention | Phase |
|---|---|---|
| Postmenopausal Osteoporosis | Drug: Teriparatide Drug: Risedronate Drug: Placebo Drug: Calcium Drug: Vitamin D | Phase 4 |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Intervention Model: Parallel Assignment Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor) Primary Purpose: Treatment |
| Official Title: | Teriparatide and Risedronate in the Treatment of Patients With Severe Postmenopausal Osteoporosis: Comparative Effects on Vertebral Fractures |
Resource links provided by NLM:
Further study details as provided by Eli Lilly and Company:
Primary Outcome Measures:
- Proportion of Participants with New Vertebral Fractures [ Time Frame: Baseline through 24 Months ]
Secondary Outcome Measures:
- Proportion of Participants with Pooled New and Worsening Vertebral Fractures [ Time Frame: Baseline through 24 Months ]
- Proportion of Participants with Pooled Clinical Vertebral and Non-Vertebral Fragility Fractures [ Time Frame: Baseline through 24 Months ]
- Proportion of Participants with Non-Vertebral Fragility Fractures [ Time Frame: Baseline through 24 Months ]
- Proportion of Participants with Major Non-Vertebral Fragility Fractures [ Time Frame: Baseline through 24 Months ]
- Proportion of Participants with New Moderate and/or Severe Vertebral Fractures [ Time Frame: Baseline through 24 Months ]
- Proportion of Participants with New Multiple (2 or more) Vertebral Fractures [ Time Frame: Baseline through 24 Months ]
- Proportion of Participants with Pooled Fragility and Traumatic Non-Vertebral Fractures [ Time Frame: Baseline through 24 Months ]
- Change from Baseline to 24 Months Endpoint in Height [ Time Frame: Baseline, 24 Months ]
- Change from Baseline to 24 Month Endpoint in Back Pain using an 11-point Numerical Pain Rating Scale [ Time Frame: Baseline, 24 Months ]
- Change from Baseline to 24 Month Endpoint in the European Quality of Life Questionnaire [EQ-5D-5L] [ Time Frame: Baseline, 24 Months ]
| Enrollment: | 1327 |
| Study Start Date: | October 2012 |
| Study Completion Date: | July 2016 |
| Primary Completion Date: | July 2016 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
Experimental: Teriparatide
Teriparatide 20 microgram (µg) administered by subcutaneous (SC) injection once daily for 24 months. Placebo given orally once weekly for 24 months. Elemental Calcium 500 to 1000 milligram per day and Vitamin D 400 to 800 International Units per day, both administered orally once daily while receiving treatment. |
Drug: Teriparatide
Administered SC
Other Names:
Drug: Placebo
Teriparatide arm placebo administered orally. Risedronate arm placebo administered SC. Administered orally
Drug: Vitamin D
Administered orally
|
|
Active Comparator: Risedronate
Risedronate 35 milligram (mg) administered orally once weekly for 24 months. Placebo given by SC injection once daily for 24 months. Elemental Calcium 500 to 1000 milligram per day and Vitamin D 400 to 800 International Units per day, both administered orally once daily while receiving treatment. |
Drug: Risedronate
Administered orally
Drug: Placebo
Teriparatide arm placebo administered orally. Risedronate arm placebo administered SC. Administered orally
Drug: Vitamin D
Administered orally
|
Eligibility| Ages Eligible for Study: | 45 Years and older (Adult, Senior) |
| Sexes Eligible for Study: | Female |
| Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria:
- Postmenopausal women with osteoporosis, as defined by low bone mineral density (BMD), i.e. anterior-posterior lumbar spine, total hip or femoral neck BMD ≥1.5 standard deviations below the average BMD for young, healthy, non-Hispanic, Caucasian women
- A minimum of 2 moderate or 1 severe vertebral fragility fractures (confirmed by central reader) are required
Exclusion Criteria:
- Increased risk of osteosarcoma
- History of unresolved skeletal diseases that affect bone metabolism
- History of atypical subtrochanteric or diaphyseal femoral fractures
- Abnormally high or low calcium levels
- Abnormally high parathyroid hormone (PTH) levels
- Severe vitamin D deficiency
- Abnormal thyroid function not corrected by therapy
- History of malignant neoplasms in the last 5 years
- Active liver disease, clinical jaundice
- Significant impairment of hepatic or renal function
- History of nephro- or urolithiasis
- Previous or planned kypho- or vertebroplasty
- Active or risk for osteonecrosis of the jaw
- Active or recent history of upper gastrointestinal disorders
- Unable to stand or sit in the upright position for at least 30 minutes
Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study.
To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below.
For general information, see Learn About Clinical Studies.
Please refer to this study by its ClinicalTrials.gov identifier: NCT01709110
Show 103 Study Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01709110
Show 103 Study Locations
Sponsors and Collaborators
Eli Lilly and Company
Investigators
| Study Director: | Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST) | Eli Lilly and Company |
More Information
| Responsible Party: | Eli Lilly and Company |
| ClinicalTrials.gov Identifier: | NCT01709110 History of Changes |
| Other Study ID Numbers: |
14536 B3D-EW-GHDW ( Other Identifier: Eli Lilly and Company ) 2012-000123-41 ( EudraCT Number ) |
| Study First Received: | October 16, 2012 |
| Last Updated: | July 14, 2016 |
Keywords provided by Eli Lilly and Company:
|
Bone Loss Vertebral fractures |
Additional relevant MeSH terms:
|
Osteoporosis Osteoporosis, Postmenopausal Spinal Fractures Bone Diseases, Metabolic Bone Diseases Musculoskeletal Diseases Spinal Injuries Back Injuries Wounds and Injuries Fractures, Bone Vitamins Vitamin D |
Ergocalciferols Calcium, Dietary Teriparatide Risedronate Sodium Etidronic Acid Micronutrients Growth Substances Physiological Effects of Drugs Bone Density Conservation Agents Calcium Channel Blockers Membrane Transport Modulators Molecular Mechanisms of Pharmacological Action |
ClinicalTrials.gov processed this record on August 18, 2017